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Kaposi’s sarcoma is a multifocal vascular lesion of low-grade potential that is most often
present in mucocutaneous sites and usually also affects lymph nodes and visceral organs.
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Cutaneous
hemoptysis associatedwith pulmonary lesions. In the early 1980s, the appearance of several
cases of Kaposi’s sarcoma in homosexual men was the ﬁrst alarm about a newly identiﬁed
epidemic, acquired immunodeﬁciency syndrome. In 1994, it was ﬁnally demonstrated that
thepresence of aherpes virus associatedwithKaposi’s sarcomacalledHHV-8 orKaposi’s sar-
coma herpes virus and its genetic sequence was rapidly deciphered. The prevalence of this
virus is very high (about 50%) in some African populations, but stands between 2% and 8%
for the entire world population. Kaposi’s sarcoma only develops when the immune system
is depressed, as in acquired immunodeﬁciency syndrome, which appears to be associated
with a speciﬁc variant of the Kaposi’s sarcoma herpes virus.
There are no treatment guidelines for Kaposi’s sarcoma established in Brazil, and thus
the Brazilian Society of Clinical Oncology and the Brazilian Society of Infectious Diseases
developed the treatment consensus presented here.
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Introduction
General aspects of Kaposi’s sarcoma
Kaposi’s sarcoma is a multifocal vascular lesion of low-grade
potential that is most often present in mucocutaneous sites
and usually also affects lymph nodes and visceral organs.1
Kaposi’s sarcoma was ﬁrst described in 1872 by Hungarian
dermatologist Moritz Kaposi. From that time to the identi-
ﬁcation of human immunodeﬁciency virus (HIV) associated
with acquired immunodeﬁciency syndrome (AIDS), Kaposi’s
sarcoma remained a rare tumor. While most of the cases iden-
tiﬁed in Europe and in North America occurred in elderly
men of Italian descent or Eastern European Jews, the neopla-
sia also occurs in several other different populations: young
black African men, children in pre-adolescence, receivers of
allergenic renal transplant and other patients treated with
immunosuppressive therapy. The disseminated and fulmi-
nant formofKaposi’s sarcomaassociatedwithAIDS is referred
to as epidemic Kaposi’s sarcoma to distinguish it from the
classical, African and transplant-related forms. In addition,
Kaposi’s sarcoma was identiﬁed in homosexual men without
HIV virus.2,3
Although the histopathology of different types of Kaposi’s
tumors is essentially identical among the various affected
groups, the clinical manifestations and course of the disease
differ dramatically.2 A key to understanding the pathogene-
sis of Kaposi’s sarcoma was the discovery in 1994 of a gamma
herpes virus, human herpes virus type 8 (HHV-8), also known
as herpes virus of Kaposi’s sarcoma.4 HHV-8 has been iden-
tiﬁed in tissue biopsies of Kaposi’s sarcoma of virtually all
patients with different forms of the disease (classical, African,
transplant-relatedandAIDS-associated), butwasabsent in the
tissue not involved by the neoplasia.2
Considered a rare disease, Kaposi’s sarcoma in its classical
form occurs more often in males, with a ratio of about 10–15
men for every woman affected. Among Americans and Euro-
peans, the usual age of onset is between 50 and 70 years of
age.2
In the 1950s, Kaposi’s sarcoma was recognized as a rela-
tively common endemic neoplasia in native populations of
equatorial Africa, comprising about 9% of all cancers seen in
males in Uganda. In Africa, indolent or locally more aggres-
sive forms of Kaposi’s sarcoma occur at a man/woman ratiolsevier Editora Ltda.
comparable to that observed for the classical tumor seen in
North America and Europe. However, patients in Africa are
signiﬁcantly younger than European patients. A lymphadeno-
pathic form is also seen in Africa, primarily in children in
preadolescence, at a male/female ratio of 3 cases to 1,2,5 and
mortality rate of nearly 100% in 3 years.5,6
In 1969, the ﬁrst case of Kaposi’s sarcoma associated with
immunosuppressive therapy in a patient with renal trans-
plantation was described. Since then, it has been observed
that several patients receiving renal transplants and other
allergenic transplants who were treated with prednisone and
azathioprine developed Kaposi’s sarcoma shortly after ini-
tiation of immunosuppressive therapy.2,7 Estimates of the
incidence of Kaposi’s sarcoma among renal transplant recip-
ients subjected to immunosuppressive therapy are between
150 and 200 times higher than the expected incidence of the
tumor in the general population. The average time to develop
Kaposi’s sarcoma after transplantation is 16 months.2
Epidemiological aspects of epidemic Kaposi’s sarcoma
In 1981, a disseminated and fulminant form of Kaposi’s sar-
coma was described in homosexual or bisexual men and was
ﬁrst reported as part of an epidemic now known as AIDS.8 The
etiology of AIDS is a retrovirus with tropism for T lymphocytes
known as HIV.9 The immune deﬁciency that characterizes
AIDS is a profound disorder of cell-mediated immune func-
tions. This immune dysfunction and deregulation of the
immune system predispose patients to the development of a
wide range of opportunistic infections and unusual neoplasm
such as Kaposi’s sarcoma. HIV can play an indirect role in the
development of Kaposi’s sarcoma.9 Approximately 95% of all
cases of epidemic Kaposi’s sarcoma in the United States were
diagnosed inhomosexual or bisexualmen. In thepast, approx-
imately 26% of all male homosexuals with HIV presented with
or developed Kaposi’s sarcoma over the course of AIDS. As a
comparison, less than 3% of all heterosexual injection drug
users with HIV developed Kaposi’s sarcoma. The proportion
of AIDS patients with Kaposi’s sarcoma has declined dra-
matically since the outbreak of the disease was identiﬁed in
10
Este é um artigo Open Access sob a licença de CC BY-NC-ND1981. About 48% of patients diagnosed with AIDS in 1981
presented with Kaposi’s sarcoma at diagnosis. By August 1987,
this proportion had declined to less than 20%. The introduc-
tion of highly active antiretroviral therapy (HAART) delayed or
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Fig. 1 – Incidence of Kaposi’s sarcoma – Brazil 1980 to June/2012.
Mini
p
a
s
a
w
K
b
(
t
n
F
s
w
a
C
T
v
t
o
l
c
p
a
e
l
a
v
e
d
e
i
a
c
c
t
P
i
t
H
i
nSource: SINAN –
revented the emergence of HIV strains resistant to treatment
nd profoundly decreased viral load, leading to increased
urvival and decreased incidence of opportunistic infections
mong AIDS patients.11,12 The use of HAART is associated
ith a substantial and sustained decline in the incidence of
aposi’s sarcoma among patients with AIDS.13–15
In Brazil, cases of Kaposi’s sarcoma related to AIDS must
e reported to the Information System for Notiﬁable Diseases
SINAN), which is fed mainly by the reporting and investiga-
ion of cases of diseases and conditions which appear on the
ational list of diseases subject to compulsory notiﬁcation.
ig. 1 shows a graph with the number of new cases of Kaposi’s
arcoma since the beginning of the epidemic to 06.30.201216:
e observe a decline in disease incidence following the avail-
bility of HAART in 1996.
linical manifestations of epidemic Kaposi’s sarcoma
he epidemic or AIDS-related Kaposi’s sarcoma has a highly
ariable clinical course, and can appear as minimal mucocu-
aneous disease or as disseminated disease with involvement
f other organs. The lesions can involve the skin, oral mucosa,
ymph nodes and visceral organs. Most patients present with
utaneous disease, but occasionally the visceral disease may
recede cutaneous manifestation. Skin lesions can occur at
ny location, but are typically concentrated in the lower
xtremities and the head and neck. The lesions can be macu-
ar, papular, nodular or look like plaques, and they are almost
ll palpable and non-pruritic. The size of the skin lesions can
ary from a few millimeters to several centimeters in diam-
ter, and can be brown, pink or violet. The lesions can be
iscrete or conﬂuent and typically appear in a symmetrical lin-
ar distribution along tension skin lines. Mucous membrane
nvolvement is common (e.g., palate, gum and conjunctiva),
nd ulcerated or bulky tumors can interfere with speech and
hewing. The lymphedema associated with the tumor, typi-
ally manifested in the lower extremities or the face, seems
o be caused by secondary obstruction of lymphatic vessels.
ain when walking can be present in the case of lesions
nvolving the soles. Lesions can occur anywhere in the gas-
rointestinal tract, usually an indicator of more advanced
IV infection, manifesting itself through symptoms that
nclude odynophagia, dysphagia, nausea, vomiting, abdomi-
al pain, hematemesis, hematochezia, melena or intestinalstry of Health.16
obstruction. Pulmonary involvement can be difﬁcult to dis-
tinguish from opportunistic infections and can be expressed
by cough, dyspnea, hemoptysis, or chest pain. Pulmonary
lesions can be an asymptomatic radiographic ﬁnding and
pleural effusions are often exudative and hemorrhagic. Lym-
phadenopathy can be the only manifestation of the disease,
which requires a lymphnodebiopsy and can lead to signiﬁcant
lymphedema.1,17–20
The introduction of HAART in order to control HIV has
caused a major change in the behavior of Kaposi’s sar-
coma related to AIDS: it was accompanied by a dramatic
decrease in incidence of disease and its less aggressive pre-
sentation, but the disease remains a severe problem in the
Western world, as in the case of its manifestation with
pulmonary involvement.21,22 HAART can cause partial or
complete regression of Kaposi’s sarcoma, with partial or com-
plete disappearance of spindle-shaped cells.23 Exacerbation
of Kaposi’s sarcoma (ﬂare) can be seen after corticosteroid
therapy or rituximab or as part of the immune reconstitu-
tion inﬂammatory syndrome which can occur upon initiation
of HAART by patients. The immune reconstitution inﬂamma-
tory syndrome is a pathological exaggerated inﬂammatory
response that is due to an exuberant immune response to
opportunistic infections either apparent or concealed, or can-
cers. The exacerbation mechanism of Kaposi’s sarcoma after
treatment with corticosteroids appears to be linked to an
upregulation of the expression of steroid receptors.24,25
Diagnosis of epidemic Kaposi’s sarcoma
Although a presumptive diagnosis of Kaposi’s sarcoma can be
often made based on the clinical history and appearance of
skin lesions, this hypothesis should be conﬁrmed by biopsy
of the lesions, whenever possible. Biopsy is especially impor-
tant for atypical lesions that are associated with systemic
symptoms or progress rapidly toward discarding bacillary
angiomatosis.26 There are three histological ﬁndings that are
characteristic of Kaposi’s sarcoma, both in cutaneous and
visceral forms: angiogenesis, inﬂammation and proliferation.
The lesions usually present two main abnormalities, which
are spindle-shaped cells, arranged in a snail-like form with
leukocyte inﬁltration and neovascularization with abhorrent
proliferation of small vessels. These tiny vessels lack a base-
line membrane, which gives rise to microhemorrhages and
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Table 1 – ACTG – classiﬁcation of Kaposi’s sarcoma.
Low risk (0)
Any of the following ﬁndings
High risk (1)
Any of the following ﬁndings
Tumor Conﬁned to the skin and/or lymph node
and/or minimum oral diseasea
• Edema or ulceration associated with tumor
• Extensive oral disease
• Gastrointestinal disease
• Visceral disease other than lymph node
Immune system CD4 cells ≥200L−1 CD4 cells <200L−1
Systemic disease • Absence of history of opportunistic
infections or canker sores
• Absence of symptoms B
• Performance status (PS) ≥70
• History of opportunistic infections or canker
sores
• Presence of symptoms B
• Performance status <70
• Another HIV related disease (neurological,
lymphoma)
ained
Clina Non-nodular disease conﬁned to the palate; symptoms B=unexpl
more than 2 weeks; PS=Karnofsky scale; adapted from ACTG–AIDS
deposition of hemosiderin in tissue. With the progression of
the disease, lesions evolve from stain to plaques and then to
a nodular form. The standard histological characteristic does
not differ among the epidemiological groups affected by the
disease.27 Additional supplementary testsmight beneeded for
patients with systemic symptoms which might mean visceral
involvement of the disease.28
Staging and prognostic factors
There is no universally accepted classiﬁcation available for
epidemic Kaposi’s sarcoma, and staging schemes that incor-
porate laboratory parameters and clinical ﬁndings have been
proposed. The majority of patients with epidemic Kaposi’s
sarcoma do not die due to the disease; factors other than
the tumor load are apparently involved in the survival of
patients. The conventions used to stage Kaposi’s sarcoma and
the methods used to assess the beneﬁts of treatment continue
to evolve because of changes in the treatment of AIDS and
the recognition of the shortcomings of the standard evalu-
ation of the tumor. The clinical course of Kaposi’s sarcoma,
treatment selection and response to treatment are strongly
inﬂuenced by the subjacent degree of immune deﬁciency and
the occurrence of opportunistic infections. The AIDS Clinical
Trials Group [ACTG] Oncology Committee published criteria
for the evaluation of epidemic Kaposi’s sarcoma. The staging
system incorporates measures of disease extent, severity of
immunodeﬁciency and presence of systemic symptoms. As
can be seen in Table 1, ACTG criteria categorize the extent of
the tumor as localized or disseminated, CD4 cell count as high
or low, and systemic disease as absent or present.29
A subsequent prospective analysis of 294 patients who par-
ticipated in clinical studies for Kaposi’s sarcoma of the ACTG
group between 1989 and 1995 showed that each variable of
Table 1 (tumor, immune system and systemic disease) was
independently associated with patient survival.30 Multivari-
ate analyses showed that worsening of the immune system
was the most important individual predictor of survival. In
patients with relatively high CD4 cell counts, tumor stage
was predictive; a CD4 count of 150 cells/mm3 can be a bet-
ter discriminating index than the limit of 200 cells initially
adopted.31,32 None of the previous studies was conducted in afever, night sweats, >10% weight loss or persistent diarrhea lasting
ical Trials Group Oncology Committee.
timewhenHAARTwas already readily available. The impact of
this therapy on survival in cases of Kaposi’s sarcoma requires
continued evaluation.31–34
In 2003, an Italian study grouppublished a research in order
to evaluate new prognostic factors and validate the ACTG
staging system for Kaposi’s sarcoma related to AIDS in the
HAART era. Clinical, epidemiological, and staging informa-
tion, as well as survival data were collected from 211 patients
with AIDS-related Kaposi’s sarcoma included in two Italian
cohort studies on HIV as of 1996, the year in which HAART
became available in Italy. In light of the results, researchers
proposed to reﬁne the application of the stage system in
which the immune system should be eliminated with a deter-
mining prognosis and only the extent of the tumor (T) and
systemic disease (S) should be regarded as predictive variables
of survival. Two categories of risk for death were identiﬁed:
(a) high risk (T1S1) and low risk (T0S0, T1S0 and T0S1). In
addition, researchers showed that pulmonary involvement
predicts survival better than the extent of the tumor and
identiﬁes the category with the highest risk regardless of the
variable S (systemic disease). Noteworthy, survival analysis of
the interaction between pulmonary disease and systemic dis-
ease appears to provide a better distribution of risk among
groups of patients, with hazard ratios (HR) progressive toward
death (Tp1S1>Tp1S0>Tp0S1>Tp0S0) when compared to the
interaction between the classical extent of the tumor and sys-
temic disease.35
Therapeutic approach in epidemic Kaposi’s
sarcoma
Although the beneﬁts of the use of HAART are indisputable,
Kaposi’s sarcoma has not disappeared as a clinical problem.
Due to the fact that HAART can induce tumor regression and
that the appropriate treatment of HIV infection requires the
administration of that therapy, distinguishing the antitumor
effects of HAART from those induced by a chemotherapeutic
21,22agent for Kaposi’s sarcoma presents difﬁculties. Moreover,
as described below, the scientiﬁc evidence suggests that tumor
response to isolated use of HAART occurs mainly in patients
who were not using this therapy.
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Major treatment goals are to relieve symptoms, prevent
isease progression and decrease the size of the tumor to
lleviate edema, involvement of a possible affected organ and
sychological stress.36 Many low-risk patients in accordance
ith the ACTG (AIDS Clinical Trials Group Oncology Com-
ittee) classiﬁcation present tumor regression with HAART
lone.37 High-risk patients usually require the combination of
AART and chemotherapy, which is suspended after disap-
earance of skin lesions.37
AART
here are no randomized clinical trials comparing the treat-
ent of Kaposi’s sarcoma with HAART versus the treatment
ithout HAART, since it is virtually recommended for all
atients with AIDS-related Kaposi’s sarcoma.61 The introduc-
ion of this therapy is associated with a substantial decrease
n the incidence and severity of cases of Kaposi’s sarcoma
ecently diagnosed in patients with HIV infection. A French
tudy that analyzed a database with 54,999 patients with
ver 180,000 patient-years of follow-up showed that the inci-
ence rate of Kaposi’s sarcoma dropped from 32 per 1000
erson-years in 1993–1994 down to 3 per 1000 person-years
fter 1999.38 Furthermore, the incidence of visceral involve-
ent by Kaposi’s sarcoma upon diagnosis dropped from over
0% to less than 30%.38 A Swiss cohort study showed that
he relative risk of development of Kaposi’s sarcoma between
997 and 1998 (HAART era) compared to the time period
etween 1992 and 1994 (pre-HAART era) was 0.08 (95% CI,
.03–0.22).39 The addition of HAART to systemic chemother-
py also increased the survival of patients with pulmonary
nvolvement by Kaposi’s sarcoma.40
Observational studies indicate that the natural history of
IDS-related Kaposi’s sarcoma has changed since the intro-
uction of HAART, along with decreased tumor incidence.41,31
retrospective study that analyzed cases of Kaposi’s sar-
oma in a database of 4439 people with HIV infection from
re-HAART therapy (1990–1996) and after the introduction of
AART therapy (1997–2002) showed that the mean count of
D4 cells and mean levels of HIV RNA were similar in the
66 patients pre-HAART and in the 40 patients in the HAART
ra. However, the overall risk of death was signiﬁcantly lower
n the HAART era (HR, 0.24).31 Due to the control of HIV
nfection, immune reconstitution is the most likely expla-
ation for this changed prognosis, much more than a direct
ffect on the tumor. Although inhibitors of HIV protease have
ntiangiogenic properties and block the development andpro-
ression of lesions resembling Kaposi’s sarcoma in mice,42
here was no difference in the possibility of clinical response
ssociated with the use of these agents.41,43 Furthermore, the
ecreased incidence of Kaposi’s sarcoma has been observed
ith the use of treatment regimens that do not contain pro-
ease inhibitors.38 Recent chemotherapy is associatedwith the
mprovement of Kaposi’s sarcoma; recent low viral load of HIV
nd HAART are associated with the improvement and res-
lution of Kaposi’s sarcoma. The response is not associated
ith the type of HAART regimen (inhibitor of non-nucleoside
everse transcriptase, protease inhibitor, or enhanced with
rotease inhibitor ritonavir).444;18(3):315–326 319
Although treatment with HAART promotes increased
counts of CD4 cells to levels above those typically associ-
ated with increased susceptibility to infection, some patients
develop AIDS-related Kaposi’s sarcoma despite the appar-
ent correction of their immunodeﬁciency.45 In some patients
with HIV who have Kaposi’s sarcoma disease (moderate to
advanced) HAART used in isolation may not be sufﬁcient
to tumor treatment, making it necessary to use other adju-
vant therapy such as systemic chemotherapy, which showed
goodefﬁcacy and resulted in signiﬁcant clinical improvements
when combined with antiretroviral therapy, as demonstrated
byphase III studies comparingHAART in isolationwithHAART
combined with systemic chemotherapy.46–49 A systematic
reviewcarried out in thepost-HAARTerawith the aimof deter-
mining whether patients with advanced Kaposi’s sarcoma can
respond to HAART in isolation was not explanatory. Of the
available studies, there were only ﬁve cases in which patients
with advanced Kaposi’s sarcoma (T1) responded to HAART in
the absence of concomitant therapy for the disease.37
Immune reconstitution inﬂammatory syndrome
The expression “immune reconstitution inﬂammatory syn-
drome” is used to describe a series of host responses that
can occur soon after the start of HAART and has been
linked to the progression of Kaposi’s sarcoma in three to six
weeks after initiation of treatment. The relationship between
immune reconstitution inﬂammatory syndrome and Kaposi’s
sarcoma was shown in two studies: (1) a series of cases of
150 treatment-naïve patients who presented with Kaposi’s
sarcoma, 10 (7%) developed tumor progression when HAART
was initiated; the risk of the immune reconstitution inﬂam-
matory syndrome seemed enhanced in patients with higher
counts of CD4 cells or with edema associated with Kaposi’s
tumor; despite tumor progression, maintenance of HAART
therapy was possible in those patients50; (2) in another series
of nine patients in an institution, progression of Kaposi’s sar-
coma occurred in an average of ﬁve weeks after initiation of
HAART therapy andwas associatedwith increases in CD4 cells
and decrease in viral load; in all patients in whom systemic
chemotherapy was used we observed tumor regression, and
interruption of antiretroviral therapy was not necessary.51
Antiviral agents
AlthoughHHV-8 viremia is associatedwith an increased risk of
developing Kaposi’s sarcoma,52 there is currently no consen-
sus on the therapeutic beneﬁts of the use of antiviral drugs
in this group of patients. In vitro studies demonstrating sen-
sitivity of HHV-8 to antiviral agents are in disagreement. One
study demonstrated that HHV-8 is sensitive to antiviral agents
such as cidofovir and gancyclovir, and weakly sensitive to acy-
clovir. However, these drugs do not act in the latent formof the
virus and it is unlikely they are effective against established
tumor lesions.53 Another study, however, found no sensitivity
to acyclovir but showed activity to gancyclovir, foscarnet and
54cidofovir, also in the replicative phase. In a clinical study
of patients with AIDS and cytomegalovirus retinitis, patients
who were treated with oral or intravenous gancyclovir had
reduced risk of developing KS.55 However, the drugs studied to
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Table 2 – Epidemic Kaposi’s sarcoma – therapeutic
approaches.
Local treatment
Retinoids Radiotherapy
Intralesional
chemotherapy
Systemic treatment
Chemotherapy
• Liposomal doxorubicin
• Liposomal daunorubicin
• Bleomycin
• Vincristine, vinblastine
• Paclitaxel
date have important systemic effectswith intravenous admin-
istration,making their prophylactic use impractical in the long
run.
Local treatments
Small localized lesions of Kaposi’s sarcoma were treated using
electro dissection and curettage, cryotherapy, or through sur-
gical excision in the pre-HAART era. Kaposi’s tumors are also
generally very responsive to local radiotherapy, with excellent
results being obtained with 20Gy or slightly higher doses.56–58
Radiation therapy is generally reserved for treating localized
skin areas and in the oral cavity. It is less used to con-
trol pulmonary lesions, lesions of the gastrointestinal tract
or other sites of Kaposi’s sarcoma. Localized lesions also
tend to be effectively treated with intralesional injections of
vinblastine.59 Alitretinoin gel 0.1% was also effective in local
control of the lesions of Kaposi’s sarcoma in aprospectivemul-
ticenter randomized trial inwhich the substancewasused two
times a day for 12 weeks; overall response rate was 37%.60
Cytotoxic agents
In epidemic Kaposi’s sarcoma, systemic chemotherapy is gen-
erally used in patients with advanced disease or when there
is evidence of rapid disease progression.61 When treatment
is indicated, the use of pegylated liposomal doxorubicin or
liposomal daunorubicin is usually recommended as ﬁrst line
treatment.61 Other chemotherapeutic agents also used in the
treatment of epidemic Kaposi’s sarcoma include bleomycin,
vincristine, vinblastine, etoposide andpaclitaxel asmonother-
apy or in combination therapy.61,62 Indications generally
accepted for the use of systemic chemotherapy as adju-
vant therapy to antiretroviral agents include: (a) extensive
involvement of skin (e.g., more than 25 lesions), (b) exten-
sive cutaneous Kaposi’s sarcoma that does not respond to
local treatment, (c) extensive edema, (d) symptomatic visceral
involvement and (e) immune reconstitution inﬂammatory
syndrome.61 The mode of use of various drugs considered in
chemotherapy for the treatment of Kaposi’s sarcoma is brieﬂy
described in Table 2.
Liposomal anthracyclines, doxorubicin and daunorubicin
constitute a considerable advance in the chemotherapy of
Kaposi’s sarcoma. The advantages of liposomal formulation
include increased drug uptake by the tumor, which leads to
a more favorable pharmacokinetic proﬁle. Clinical studies of14;18(3):315–326
liposomal anthracyclines in the treatment of Kaposi’s sarcoma
associated with HIV/AIDS were conducted in pre-HAART era,
but clinicians continue to regard them as ﬁrst-line treatment
agents of Kaposi’s sarcoma. Both liposomal daunorubicin
(40mg/m2 every two weeks) and pegylated liposomal doxo-
rubicin (20mg/m2 every two to three weeks) showed good
antitumor activity. Toxicity proﬁle of both agents is better
than that of other anthracyclines, and there are no reports
of either cardiotoxicity or signiﬁcant alopecia, even with
high cumulative doses. However, these agents still cause
signiﬁcant myelosuppression and occasional emesis. In addi-
tion, infusion-related hypotension and hand-foot syndrome
are new adverse events seen with the use of such liposo-
mal formulations.61 A phase III randomized study comparing
liposomal daunorubicin and ABV regimen (doxorubicin,
bleomycin and vincristine) revealed no difference in terms of
overall response rates (partial response+ complete response),
time to treatment failure and survival duration.63 Two ran-
domized phase III studies compared pegylated liposomal
doxorubicin with conventional chemotherapy combinations
(ABV in a study and BV [bleomycin+vincristine] in another)
as ﬁrst-line treatment for patients with Kaposi’s sarcoma
who were not receiving HAART. The two studies showed that
response rates were higher among groups of patients who
received pegylated liposomal doxorubicin, but responseswere
not sustained over time.64,65 The three studiesmentioned can-
not be directly compared. A small randomized study included
79 patients with Kaposi’s sarcoma who were randomized to
receive pegylated liposomal doxorubicin (20mg/m2) or liposo-
mal daunorubicin (40mg/m2) every two weeks for up to six
cycles. Differences have been shown favoring pegylated lipo-
somal doxorubicin.66
Myelosuppression (e.g., neutropenia) is a major side effect
of pegylated liposomal doxorubicin, representing a limiting
factor in the therapeutic regimen for the treatment of neo-
plasia. Patients who develop neutropenic fever (deﬁned by the
presence of fever, oral temperature >38.3 ◦C or ≥38.3 ◦C for
more than 1h; whereas neutropenia is deﬁned as neutrophil
count <500mm−3 or between 500 and 1000mm−3 and tend to
fall in the next 48h) in the course of chemotherapy should be
carefully evaluated for whether they should receive treatment
with myeloid growth factors.67 In the case of using ﬁlgrastim,
the daily dose is 5g/kg/day, treatment should be continued
until absolute neutrophil counts reach their normal value.67
Hand-foot syndrome is a set of signs and symptoms of
acute nature affecting the palms of the hands and soles of the
feet, being strongly associatedwith antineoplastic chemother-
apy, occurring to a lesser extent in patients treated with
liposomal anthracyclines compared with other chemotherapy
agents such as 5-ﬂuorouracil and derivatives. In treatment
schemes where there is an expected rate of occurrence of
this syndrome, it is important that patients be able to recog-
nize early signs, so that therapy can be adjusted immediately.
Changes in dose or systemic and local approaches can be
used. Once symptoms have subsided, therapy can usually
be restarted according to initial planning. Upon recurrence
of symptoms, especially if more severe, dose adjustment is
required.68
Pyridoxine (vitamin B6) has shown beneﬁts as sys-
temic therapy of hand-foot syndrome. There are reports of
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omplete disappearance of hand-foot syndrome with doses
f 50–150mg daily. However, some patients may not respond
o this drug. Although the exact mechanism of action is not
et fully understood, pyridoxine can also be used prophy-
actically. Anti-inﬂammatory inhibitors of cyclooxygenase-2
COX-2) have also proven effective in the prophylaxis of hand-
oot syndrome associated with chemotherapy. High potency
orticosteroids and disinfectant treatment of vesicles and
rosions were effective when considering a topical therapy.
reventive use of glucocorticoids, by contrast, proved ineffec-
ive. Inmild cases of the syndrome, avoidmechanical irritation
f the skin on the palms of hands and soles of feet, and the use
f emollient creams or soft gels is enough for control and relief
f symptoms. Cooling of the affected areas using cold baths of
ands and feet (without intensive washing) also helps in relief
f symptoms.Depending on the severity of the syndrome, cure
ccurs in a matter of days or weeks.68
Although paclitaxel is potentially more toxic than liposo-
al anthracyclines, it has remarkable efﬁcacy as second-line
reatment of Kaposi’s sarcoma,69,70 and can be an alterna-
ive to initial therapy of patients with advanced symptomatic
isease. The effectiveness of paclitaxel was originally demon-
trated in a phase II study with 28 evaluable patients in which
0 (71%) had higher responses to the treatment regimen of
35mg/m2 every 3 weeks (18 partial responses, one full clini-
al response and one full response). Responses were observed
n all ﬁve patientswith pulmonary lesions of Kaposi’s sarcoma
nd all four patients had received prior anthracycline-based
hemotherapy. Treatment toxicity included grade 4 throm-
ocytopenia in 6 of the 29 enrolled patients and grade 4
eutropenia in 22 of the 29 patients treated without the
se of hematopoietic growth factors.71 Treatment regimen
f paclitaxel 100mg/m2 every 2 weeks was compared with
he use of pegylated liposomal doxorubicin in a dose of
0mg/m2 every 3 weeks in a randomized clinical trial con-
ucted after the introduction of routine treatment with
AART.46 In this study, 73 evaluable patients with Kaposi’s
arcoma associated with AIDS were included between 1998
nd 2002 (the trial was prematurely terminated because of
ow patient inclusion). There were no statistically signif-
cant differences between the two treatment regimens in
erms of response rate, progression-free survival or overall
urvival. The two treatment regimens propitiated consid-
rable improvement of pain and of edema secondary to
umor.46
Myelosuppression (e.g., neutropenia) induced by paclitaxel
s an important side effect, representing a limiting factor
n the therapeutic regimen for the treatment of neoplasia.
atients who develop neutropenic fever (deﬁned by the pres-
nce of fever, oral temperature >38.3 ◦C or ≥38.3 ◦C for more
han 1h; whereas neutropenia is deﬁned as neutrophil counts
500mm−3 or between 500 and 1000mm−3 and tend to fall
n the next 48h) in the course of chemotherapy should be
arefully evaluated for whether they should receive treatment
ith myeloid growth factors.67 In the case of the use of ﬁl-
rastim, the daily dose is 5g/kg/day, and treatment should
e continued until absolute neutrophil count reaches normal
alue.67
Before the era of HAART, several other chemotherapeutic
gents (e.g., bleomycin, doxorubicin, vinblastine, vincristine,4;18(3):315–326 321
and etoposide) were active in the treatment of Kaposi’s sar-
coma related to AIDS in case reports and in small phase
II trials that evaluated different combinations and doses of
these drugs.61 The percentage of patients achieving a decrease
of ≥50% in number of lesions ranged from 58% to 90%
under treatment with vinca alkaloids, from 74% to 76% with
etoposide was 97% with the combination of vinblastine and
bleomycin. However, clinical studies that evaluated these regi-
mens presented low quality due to the lack of a standardized
classiﬁcation of disease activity and clinical outcomes ana-
lyzed. Therefore, evidence for the effectiveness of any of these
treatment regimens is of low quality and does not support
recommendation of any of these regimens in particular.72
For the duration of treatment with HAART, both pegy-
lated liposomal doxorubicin and paclitaxel are isolated active
agents in the treatment of epidemic Kaposi’s sarcoma, with
response rates close to 50%.61
Immunotherapy
The use of biological response modiﬁer interferon- was
approved for the treatment of Kaposi’s sarcoma before
the availability of HAART and liposomal anthracyclines.
Interferons- were extensively studied and showed objec-
tive response rate of 40% in patients with epidemic Kaposi’s
sarcoma.73,74 In these studies, responses differed signiﬁcantly
according to the prognostic factors of disease extent, prior
or coexistent opportunistic infections, previous treatment
with chemotherapy, CD4 lymphocyte counts of less than
200 cells/mm3, presence of circulating acid-labile interferon-
and increased 2-microglobulin.
Response to interferon- often requires continuous treat-
ment for 6 months or more, since response time is typically
longer than four months. Interferon- should not be consid-
ered as a therapeutic option in case of progressive or visceral
disease. Toxicity of highdoses of interferon- (e.g., fever, chills,
neutropenia and depression) is common and low responses
are observed in the presence of low counts of CD4 cells.61
Interferon- is not very often used today due to its toxicity
proﬁle and because it does not work well in many patients
with AIDS.28
Interleukin-12 has shown a response rate of 71% (95% CI,
48–89%) in the treatment of Kaposi’s sarcoma in 24 evaluable
patients in a phase I study.75
Summary of therapeutic recommendations for
epidemic Kaposi’s sarcoma
Table 2 shows possible therapeutic approaches for patients
with epidemic Kaposi’s sarcoma. Speciﬁcally, Table 3 presents
main cytotoxic agentswhich can be used in the chemotherapy
treatment of epidemic Kaposi’s sarcoma.
Recommendationsbelow, this committee makes the following recommendations
related upon diagnosis and treatment of epidemic Kaposi’s
sarcoma.
322
b
r
a
z
j
in
f
e
c
t
d
is
.2
0
1
4
;1
8
(3
):315–326
Table 3 – Cytotoxic agents used in the treatment of epidemic Kaposi’s sarcoma.
Pegylated liposomal
doxorubicin
Daunorubicin citrate
liposome
Doxorubicin
hydrochloride
Bleomycin sulfate Vincristine sulfate Vinblastine sulfate Paclitaxel
Dose schedule 20mg/m2 every two
or three weeks
For doses <90mg:
dilute in 250ml of
glucose solution at
5% (50mg/ml). For
doses >90mg: dilute
in 500ml of glucose
solution at 5%
(50mg/ml)
40mg/m2 15/15 days
Should be diluted in
glucose solution at
5–100ml for 1mg/ml
concentration and
infused within
60min
10–20mg/m2
It should be
dissolved in 0.9%
sodium chloride or
sterile water for
injections
Recommended
concentration is
2mg/ml
10U/m2 (1U=1mg)
15/15 days
Dilute in 20ml saline
solution
Apply in 10min
0.01–0.03mg per kg
of bodyweight, as
single dose every 7
days; or 0.4 to
1.4mg/m2 of body
surface, as single
dose every 7 days
Reconstitute in
diluent provided
with the product
(benzyl alcohol) and
only administer
intravenously
Weekly dose when
isolated and 15/15
days in combination
with other
chemotherapeutic
agents
Initial dose of
3.7mg/m2 of body
surface per week
Sequential increases
should follow from
1.8 to 1.9mg/m2 of
body surface at
weekly intervals
Dilute with saline
solution at the
concentration of
1mg/ml
Administer bolus in
10–15min in “Y”
135mg/m2 every 3
weeks OR 100mg/m2
every 2 weeks
Premedicate with
diphenhydramine,
50mg EV,
dexamethasone
20mg EV and
cimetidine, 300mg
(or ranitidine, 50mg
EV) before paclitaxel
Guidelines and
precautions
The initial dose is
administered at a
rate not exceeding
1mg/min. If no
infusion reaction is
observed,
subsequent
infusions can be
administered over a
period of 60min
In cases of
palmar-plantar
erythrodysesthesia,
hematologic toxicity
and stomatitis, the
dose can be reduced
or delayed
Should not be
administered with
other
chemotherapeutic
drugs (no studies on
interactions)
Heart failure can
occur with
cumulative dose
above 300mg/m2
May cause
myelosuppression
(especially of
granulocytic series)
Leucopenia reaches
its lowest point in
10–14 days, with
Retrieval
approximately on
day 21
Cumulative dose
above 550mg/m2:
risk of heart failure.
Signiﬁcant ﬁnding
on ECG: QRS voltage
reduction
Can be used with
other
chemotherapeutic c
agents
When in
combination with
vincristine,
administer it
previously as it
increases sensitivity
to bleomycin. Risk of
pulmonary ﬁbrosis
increases with
cumulative doses
above 400U
Low myelotoxicity.
Can be associated
with other
chemotherapeutic
agents
Common occurrence
of neuropathy
Little
Myelosuppressi ve
effect
Can be used with
other
chemotherapeutic
agents
Do not administer
with doxorubicin
When administered
with bleomycin,
apply vinblastine
beforehand
Alopecia
Dose-dependent
leukopenia
Some antiretroviral
drugs are enzyme
inducers and can
interfere with the
activity of paclitaxel
by increasing
metabolism
Use G-CSF or
peg-GCSF as primary
prophylaxis when
there is risk of
neutropenic fever
>20% or secondary
to ﬁlgrastim 5
mcg/kg/day or
pegﬁlgrastim a 6mg
subcutaneousl y per
dose (only if the
interval between
cycles >2 weeks).
Note: Always start
24h after the end of
chemotherapy
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iagnostic approach
Patients with conﬁrmed KS and who ﬁt in category S1 must
be submitted to upper and lower endoscopy as well as bron-
choscopy, regardless of the presence of clinical symptoms.
If there is no contraindication, investigation of pulmonary
involvement by bronchoscopy should be performed in all
patients with KS.
Investigation of visceral lesions using endoscopic examina-
tions should be performed in symptomatic patients.
Investigation of visceral lesions using endoscopic exam-
inations should be performed in patients unable to
immediately start HAART or with virological failure to
antiretroviral therapy.
Investigation of visceral lesions using endoscopic examina-
tions should be performed in patients who developed KS in
regular use of HAART.
herapeutic approach
AART
ecause it is an AIDS-deﬁning disease, all patients should
eceive HAART, regardless of CD4 count.76
hemotherapy
Systemic chemotherapy should be initiated in:
S1T1 patients.
Patients with pulmonary involvement.
Patients with symptomatic visceral lesions.
Patients with lymphedema secondary to Kaposi’s sarcoma.
Patients with rapidly progressive skin disease.
Patients with progression of clinical disease after introduc-
tion of HAART.
Patients with immune reconstitution inﬂammatory syn-
drome by Kaposi’s sarcoma.
Patients who developed Kaposi’s sarcoma in regular use of
HAART, regardless of disease stage.
Systemic chemotherapy should be considered:
Patients unable to immediately start HAART or with current
virological failure to antiretroviral therapy.
Patients with cosmetically disﬁguring lesions that did not
respond to local therapy.
For initial chemotherapy treatment, it is recommended to
use a liposomal anthracycline (either pegylated liposomal
doxorubicin or liposomal daunorubicin [evidence level 1b]).
Other cytotoxic agents can be used in combination in loca-
tions where liposomal anthracyclines are not available.
For patients whose disease has progressed following treat-
ment with liposomal anthracycline, it is recommended to
use chemotherapy with paclitaxel (evidence level 3B).
For patients who present Kaposi’s sarcoma or limited dis-
ease causing symptoms or cosmetic disﬁgurement, it is
recommended to use local treatment adjuvant to HAART
(evidence level 2C).
For patients who present small lesions, it is recommended
to use intralesional chemotherapy (evidence level 2C); for
those patients with greater lesions that cannot be treated4;18(3):315–326 323
with intralesional chemotherapy and who do not have an
indication of systemic chemotherapy, it is recommended to
use radiotherapy (evidence level 2C).
- Liposomal anthracyclines cannot be used in combination
with other drugs.
- Cytotoxic agents vincristine, bleomycin and doxorubicin
(non-liposomal formulation) can be used in isolation or in
combination. The sum of the adverse effects of the respec-
tive drugs should be monitored.
Criteria of response to chemotherapy
Deﬁnitions recommended for criteria of response to
chemotherapy29 are described below.
Full response (FR): absence of any detectable residual dis-
ease, including tumor-associated edema, persisting for at least
4 weeks. In patients in whom macular pigment (brown or
beige) skin lesions persist after apparent FR, biopsy of at least
one representative lesion is required to document the absence
of malignant cells. In patients known to have had visceral dis-
ease, revaluation with appropriate endoscopic or radiological
procedures should be made. If there are contraindications for
such procedures the patient can be classiﬁed as having clinical
FR.
Partial response (PR): a decrease of 50% or more in the num-
ber and/or size of pre-existing lesions maintained for at least
4 weeks without the appearance of new skin lesions or oral
lesions or visceral lesions or worsening of effusions/edema
associated with the tumor, or an increase of 25% or more in
the product of two-dimensional diameters of any indicative
lesion.
Stable disease: any response that does not meet criteria for
partial response (PR) or progressive disease.
Progressive disease: an increase greater than or equal to 25%
in the number or size of pre-existing lesions and/or appear-
ance of new lesions.
In patients with an indication for systemic chemotherapy,
this committee recommends that treatment be discontinued
in the following situations:
• after regression of cutaneous lesions;
• after complete remission of lesions in the respiratory tract,
if any;
• after remission of symptoms in visceral lesions, if any;
• if there is evidence of clinical beneﬁt of continuing treat-
ment.
Final considerations
Above recommendations have been prepared considering the
prognosis of patients with Kaposi’s sarcoma in use of HAART.
Where this therapy is not used for any reason, patients with
visceral lesions, even asymptomatic, should be considered
in accordance with the classiﬁcation of ACTG (AIDS Clinical
Trials Group Oncology Committee) and treatment should be
optimized.Conﬂicts of interest
The authors declare no conﬂicts of interest.
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Appendix A. Levels of scientiﬁc evidence used in guidelines (according to the Oxford Centre for
Evidence-Based Medicine)
evel of recom-
endation
Evidence level Treatment/prevention-etiology Diagnosis
1A Systematic review (with homogeneity)
of RCTs
Systematic review (with homogeneity) of
level 1 diagnostic studies, level 1B diagnostic
criterion, in different clinical centers
1B RCT using narrow CI Validated cohort using good reference
standard, diagnostic criterion tested in a
single clinical center
1C Therapeutic results of the “all or
nothing at all” type
Sensitivity and speciﬁcity close to 100%
2A Systematic review (with homogeneity)
of cohort studies
Systematic review (with homogeneity) of
diagnostic studies level >2.
Exploratory cohort using good reference
standard, diagnostic criterion derived or
validated in fragmented samples or database
2B Cohort study (including RCTs of lower
quality)
2C Observation of therapeutic results.
Ecological study
3A Systematic review (with homogeneity)
of case-control studies
Systematic review (with homogeneity) of
diagnostic studies of level >3B
3B Case-control study Non-consecutive selection of cases or
reference standard applied in a not very
consistent manner
4 Case report (including cohort or
case-control of lower quality)
Case-control or poor reference standard or
not independent
5 Opinion without critical evaluation or
based on basic materials (physiological
study or animal study)
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